Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992 Dec;15(12):1926-75.
doi: 10.2337/diacare.15.12.1926.

Diabetic neuropathies

Affiliations
Review

Diabetic neuropathies

A I Vinik et al. Diabetes Care. 1992 Dec.

Abstract

Diabetic neuropathy is a common complication of diabetes that may be associated both with considerable morbidity (painful polyneuropathy, neuropathic ulceration) and mortality (autonomic neuropathy). The epidemiology and natural history of diabetic neuropathy is clouded with uncertainty, largely caused by confusion in the definition and measurement of this disorder. We have reviewed various clinical manifestations associated with somatic and autonomic neuropathy, and we herein discuss current views related to the management of the various abnormalities. Although unproven, the best evidence suggests that near-normal control of blood glucose in the early years after diabetes onset may help delay the development of clinically significant nerve impairment. Intensive therapy to achieve normalization of blood glucose also may lead to reversibility of early diabetic neuropathy, but again, this is unproven. Our ability to manage successfully the many different manifestations of diabetic neuropathy depends ultimately on our success in uncovering the pathogenic processes underlying this disorder. The recent resurgence of interest in the vascular hypothesis, for example, has opened up new avenues of investigation for therapeutic intervention. Paralleling our increased understanding of the pathogenesis of diabetic neuropathy, refinements must be made in our ability to measure quantitatively the different types of defects that occur in this disorder. These tests must be validated and standardized to allow comparability between studies and more meaningful interpretation of study results.

PubMed Disclaimer

Similar articles

  • Clinical aspects of diabetic neuropathies.
    Vinik A, Mitchell B. Vinik A, et al. Diabetes Metab Rev. 1988 May;4(3):223-53. doi: 10.1002/dmr.5610040304. Diabetes Metab Rev. 1988. PMID: 3293949 Review.
  • Diabetic neuropathies.
    Vinik AI, Park TS, Stansberry KB, Pittenger GL. Vinik AI, et al. Diabetologia. 2000 Aug;43(8):957-73. doi: 10.1007/s001250051477. Diabetologia. 2000. PMID: 10990072 Review.
  • Diabetic neuropathies.
    Vinik AI, Mehrabyan A. Vinik AI, et al. Med Clin North Am. 2004 Jul;88(4):947-99, xi. doi: 10.1016/j.mcna.2004.04.009. Med Clin North Am. 2004. PMID: 15308387 Review.
  • New insights in diabetic autonomic neuropathy in children and adolescents.
    Verrotti A, Loiacono G, Mohn A, Chiarelli F. Verrotti A, et al. Eur J Endocrinol. 2009 Dec;161(6):811-8. doi: 10.1530/EJE-09-0710. Epub 2009 Sep 4. Eur J Endocrinol. 2009. PMID: 19734243 Review.
  • Diabetic neuropathies: diagnosis and management.
    Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Deli G, et al. Neuroendocrinology. 2013;98(4):267-80. doi: 10.1159/000358728. Epub 2014 Jan 22. Neuroendocrinology. 2013. PMID: 24458095 Review.

Cited by

LinkOut - more resources